Adding baseline protein biomarkers to clinical predictors does not enhance prediction of treatment response to a methotrexate strategy in early rheumatoid arthritis

Xavier M. Teitsma*, Johannes W.G. Jacobs, Pascal H.P. De Jong, Johanna M.W. Hazes, Angelique E.A.M. Weel, Paco M.J. Welsing, Attila Pethö-Schramm, Michelle E.A. Borm, Jacob M. Van Laar, Johannes W.J. Bijlsma, Floris P.J.G. Lafeber

*Corresponding author for this work

Research output: Contribution to journalLetterAcademicpeer-review

Original languageEnglish
Pages (from-to)142-144
Number of pages3
JournalAnnals of the Rheumatic Diseases
Issue number1
Publication statusPublished - 1 Jan 2019


  • DMARDs (synthetic)
  • methotrexate
  • rheumatoid arthritis

Cite this